Search International and National Patent Collections

1. (WO2018205038) COMPOSITIONS COMPRISING CANNABINOIDS AND TERPENES USEFUL IN THE TREATMENT OF CANCER AND VASCULAR OCULAR DISORDERS VIA INHIBITION OF HEDGEHOG SIGNALLING

Pub. No.:    WO/2018/205038    International Application No.:    PCT/CA2018/050572
Publication Date: Fri Nov 16 00:59:59 CET 2018 International Filing Date: Tue May 15 01:59:59 CEST 2018
IPC: A61K 31/352
A61K 31/01
A61K 31/015
A61K 31/045
A61K 31/05
A61K 31/15
A61K 31/164
A61K 31/165
A61K 31/198
A61K 31/22
A61K 31/5383
A61K 31/57
A61K 36/185
C07C 11/21
C07C 13/21
C07C 13/271
C07C 13/42
C07C 233/01
C07C 233/17
C07C 233/18
C07C 39/19
C07C 39/23
C07C 69/67
C07D 311/60
C07D 311/80
C07D 498/06
Applicants: TETRA BIO-PHARMA INC.
Inventors: RINGUETTE, Randy
CAMPBELL, Charles
Title: COMPOSITIONS COMPRISING CANNABINOIDS AND TERPENES USEFUL IN THE TREATMENT OF CANCER AND VASCULAR OCULAR DISORDERS VIA INHIBITION OF HEDGEHOG SIGNALLING
Abstract:
Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of the composition synergistically inhibit HH signaling such that they serve to treat cancer and ocular disorders associated with aberrant neovascularization (such as age-related macular degeneration). The cannabinoids to be used include phytocannabinoids (such as tetrahydrocannabinol and cannabidiol), endogenous cannabinoids (such as the N-acylethanolamides), or synthetic cannabinoids. Preferred terpenes for use include those that naturally occur in Cannabis plants (such as pinene, limonene, linalool, and phytol).